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1607-551X/Copyright ª 2014, KaohsiuAbstract To investigate the effects of cerebrolysin (Cbl) on optic nerves (ON) and retinal gan-
glion cells (RGC) in a rat model of ON crush. Rats received intravitreal injection of Cbl
(nZ 20), intra-ON injection ofCbl (nZ 20), intraperitoneal injection (IPI) of Cbl (nZ 20), or phos-
phate buffered saline (PBS; nZ 20) every day for 2 weeks after ON crush injury. At 3 weeks post-
trauma, RGC density was counted by retrograde labeling with FluoroGold and visual function was
assessed by flash visual-evoked potentials. Activities of microglia after insults were quantified by
immunohistochemical analysis of thepresenceof ED1 in theoptic nerve.At 3weekspostcrush, the
densities of RGCs in the Cbl-IVI group (1125  166/mm2) and in the Cbl-IPI treatment group
(1328  119/mm2) were significantly higher than those in the PBS group (641  214/mm2). The
flash visual-evoked potential measurements showed that latency of the P1 wave was significantly
shorter in the Cbl-IVI- and Cbl-IPI-treated groups (105 4 ms and 118 26 ms, respectively) than
in the PBS-treated group (170  20 ms). However, only Cbl IPI treatment resulted in a significant
decrease in the number of ED1-positive cells at the lesion sites of the ON (5  2 cells/vs.
30 4 cells/high-power field in control eyes). Treatmentwith intra-ON injection of Cbl was harm-
ful to the optic nerve in the crush model. Systemic administration of Cbl had neuroprotective ef-
fects on RGC survival and visual function in the optic nerve crush model.
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Optic nerve (ON) injury leads to anterograde and retro-
grade degeneration, consequentially producing a scar at
the site of injury and loss of retinal ganglion cells (RGCs).
Although pulse steroid therapy is frequently used to treat
acute traumatic optic neuropathy [1], there are no
convincing data to indicate any effective treatment for
traumatic optic neuropathy. In our previous studies we
found that systemic human granulocyte colony-stimulating
factor, but not corticosteroid treatment, had a neuro-
protective effect in a rat model of optic nerve crush [2,3].
Neurotrophic factors that are upregulated by endoge-
nous opioids are not sufficient to enable the rescue of
damaged neurons [4]. Various neurotrophic factors are
present in the central nervous system after injury, including
brain-derived neurotrophic factor, nerve growth factor,
ciliary neurotrophic factor, and glial cell line-derived neu-
rotrophic factor [5]. Cerebrolysin (Cbl), the only drug
available for clinical use that contains active fragments of
some important neurotrophic factors [6,7], has been found
effective in a number of clinical trials for the treatment of
vascular dementia, stroke, and other neurodegenerative
diseases [8e12]. Studies of the effectiveness of Cbl as a
neuroregeneration treatment have been conducted in
different injury models including traumatic brain injury,
spinal cord injury, ischemic stroke, hyperthermia, drugs of
abuse, and neuropathic pain [6,7,12e17]. In this pilot study
that aimed to extend this research, we investigated
whether Cbl has neuroprotective effects in an animal model
of optic nerve crush.
Materials and methods
Cbl administration
Cbl; 215.2 mg/mL (EVER Neuro Pharma GmbH, Unterach,
Austria) was used as the target drug in this crush model.
Animals
Adult male Wistar rats weighing 150e180 g (age 7e8 weeks)
were obtained from the breeding colony of BioLASCO Co.,
Yu-Lan, Taiwan. The Institutional Animal Care and Use
Committee at the Tzu Chi Medical Center, Hualien, Taiwan
approved all animal experiments. All manipulations were
performed with standard procedures as described in our
prior paper [18].
Study design
A total of 80 rats underwent ON crush procedures in the
right eyes and sham operations in the left eyes. Rats then
received one intravitreal injection (IVI) of Cbl 2 mL
(0.43 mg; nZ 20), one intra-ON injection (IONI) of Cbl 2 mL
(0.43 mg; n Z 20), intraperitoneal injection (IPI) of Cbl
(5 mL/kg; n Z 20), or phosphate buffered saline (PBS;
n Z 20) every day for 2 weeks. Three weeks after surgery,
RGC density was measured by retrograde labeling withFluoroGold (Fluorochrome LLC, Denver, CO, USA), and vi-
sual function was assessed by flash visual-evoked potentials
(fVEP). Microglia activity after insult was quantified by
immunohistochemical analysis of ED1 expression in the
optic nerve.
Optic nerve crush injury experiments
ON crush injuries were induced as described in our previous
reports [2,18]. Briefly, a standardized vascular clip (60-g
microvascular clip; World Precision Instruments, Sarasota,
FL, USA) was then applied to the ON at a distance of 2 mm
posterior to the globe for 30 seconds. The left eyes
received a sham operation that entailed optic nerve expo-
sure without the crush procedure.
Retrograde labeling of RGCs with FluoroGold and
morphometry of the RGCs
The detailed procedures have been described in our
previous reports [2,3,18]. We performed retrograde la-
beling of the RGCs 1 week prior to when the rats were
euthanized. In brief, the rats were anesthetized and
placed in a stereotactic apparatus (Stoelting, Wood Dale,
IL, USA). The 1.5 mL of 5% FluoroGold was injected into
the superior colliculus on each side through a Hamilton
syringe. One week after the labeling, the eyeballs were
harvested after the animals had been euthanized. The
retinas, examined with a 400 epi-fluorescence micro-
scope (Axioskop; Carl Zeiss Meditech Inc., Thornwood,
NY, USA), were examined for RGCs at a distance of 1 mm
from the center to provide the central RGC densities. We
counted at least five randomly chosen areas of 62,500 mm2
each in the central regions of each retina, and their av-
erages were taken as the mean density of RGCs per retina
(n > 6 in each group).
fVEP
An isolated silver plate electrode was placed extradurally
through a 2-mm diameter craniotomy over the visual cortex
using stereotactic coordinates (bregma 8 mm, lateral
3 mm) [18,19]. We used a visual electrodiagnostic system
(UTAS-E3000, LKC Technologies, Gaithersburg, MD, USA) to
measure the fVEP [18]. When the wave was nonrecordable,
the latency of P1 was set at 200 ms for comparison.
Immunohistochemistry (IHC) of ED-1 (CD68) in the
ONs
The experiment was performed as described previously
[3,20]. In short, the primary antibody (1:50; AbD Serotec,
Oxford, UK) was applied and incubated overnight at 4C.
The secondary antibody conjugated with fluorescein iso-
thiocyanate (FITC, 1:100; Jackson ImmunoResearch Labo-
ratories, West Grove, PA, USA) was applied at room
temperature for 1 hour. Counterstaining was performed
using 40,6-diamidino-2-phenylindole (DAPI, 1:1000; Sigma,
St Louis, MO, USA). For comparison, the ED1-positive cells
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lesion site.
Statistical analysis
Data are presented as mean values with standard de-
viations. One-way analyses of variance (ANOVA) was used to
evaluate the differences between treated groups. A p value
of <0.05 was considered to represent statistical
significance.Results
RGC densities after ON crush
The mean density of RGCs in the center of normal eyes was
2535  123/mm2. Three weeks after ON crush, the mean
central RGC density was 641  214/mm2. The densities of
the RGCs in the center of the retina were significantly
higher in the Cbl-IVI group (1125  166/mm2) and the Cbl-Figure 1. Improvement in retinal ganglion cell (RGC) density in ce
(IVI) and intraperitoneal (IPI) injection was noted at the 3rd wee
2535  123/mm2. (B) RGC densities were significantly decreased in
mm2). (C) The density of RGCs was significantly higher in the Cbl-I
group (p < 0.001). (D) After Cbl intraoptic nerve injection, the d
nificant difference was noted between that group and the PBS grou
increased to 1328  119/mm2. **p < 0.001. n > 6 in each group. BIPI group (1328  119/mm2) than in the PBS group
(641  214/mm2; both p < 0.001). However, there were no
significant differences in RGC count between the Cbl-IONI
group and the PBS group (Fig. 1).
fVEP
The fVEP changes were measured 3 weeks after ON crush
induction. The latencies of the P1 wavelet were 119  1 ms
in the sham group, 170  20 ms in the PBS group, 105  4 ms
in the Cbl-IVI group, 161  35 ms in the Cbl-IONI group, and
118  26 ms in the Cbl-IPI group. Latency of the P1 wavelet
was more significantly preserved in the Cbl-IVI and Cbl-IPI
groups than in the PBS group (Fig. 2, n Z 6 in each
group, both p < 0.001). Cbl-IONI had no effect on short-
ening the latency of the P1 wavelet.
ED1 expression in optic nerves
Very few ED1-positive cells were noted in the sham group
(1  1 cells/HPF); however, a prominent number of ED1-ntral retinas after cerebrolysin (Cbl) treatment via intravitreal
k postcrush. (A) In the sham group, the density of RGCs was
the phosphate-buffered saline (PBS)-treated group (641  214/
VI treatment group (1125  166/mm2) than in the PBS-treated
ensity of RGCs increased to 924  112/mm2; however, no sig-
p. (E) After Cbl-IPI treatment, the density of RGCs significantly
ar Z 50 mm. C Z crush.
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group (30  4 cells/HPF). ED1 in the ON was detected in
33  5 cells/HPF in the IVI-Cbl group, in 39  9 cells/HPF in
the IONI-Cbl group, and in 5  2 cells/HPF in the IPI-Cbl
group. The number of ED1-positive cells was significantly
lower in the IPI-Cbl group than those of the other treatment
groups (Fig. 3, n Z 6 in each group, p < 0.001). There was
no significant difference in the number of ED1-positive cells
between the Cbl-IVI group or the Cbl-IONI group and the
PBS-treated group.Discussion
In vivo and in vitro data show that Cbl substantially aug-
ments neurogenesis and neuroplasticity [13,17,21e23]. Our
study demonstrated that the neuroprotection induced by
Cbl-IVI and Cbl-IPI may contribute to the improved visual
functional outcomes after optic nerve crush injury.
In consideration of prior clinical reports indicating the
good efficacy of subtenon injection as well as intravitreal
injection in the treatment of ocular disease, we designed
direct injection of cerebrolysin into the ON sheath (IONI)
and vitreous cavity (IVI) [24e26]. Low-molecular-weight
peptides of cerebrolysin are able to cross the bloodebrain
barrier [27] and, with its crossing, it is possible that sys-
temic cerebrolysin can pass through the blood retinal bar-
rier and induce the positive effect in neuroprotection in the
optic crush model. Although local administration of the
drug may yield better results and fewer side effects than
systemic applications in ON insults, IONI may cause addi-
tional trauma to the optic nerve, and for this reason our
data show no neuroprotection effect in the IONI group.
Applications of Cbl in different animal models have been
reported [4,14,16,17,28]. Sharma et al. [29] studied Cbl
treatment in a rat model of spinal cord injury and found
that a high dose of Cbl (5 mL/kg) was very effective in
reducing the degree of axonal changes in morphology after
injury. They also found that Cbl markedly reduced theFigure 2. Improvement in latency of P1 in flash visual-evoked po
and intraperitoneal (IPI) injection was noted at the 3rd week post
latency (105  4 ms and 118  26 ms, respectively) than the phos
p < 0.001). No significant shortening of P1 wave latency was noted
(161  35 ms vs. 170  20 ms, respectively). n Z 6 in each group.degree of neurotoxicity induced by hyperthermia [15]. In a
neurodevelopmental rat model of schizophrenia, Va´zquez-
Roque et al. [28] found that chronic administration of Cbl
ameliorates the behavioral and morphological changes
induced by lesions of the neonatal ventral hippocampus. In
addition, in a rat model of embolic artery occlusion, Zhang
et al. [17] found that Cbl treatment administered <48 hours
after stroke enhances neurogenesis and improves func-
tional outcome, Also, using a transgenic model of Alz-
heimer’s disease, Rockenstein et al. [16] found that Cbl
reduced amyloid burden and improved synaptic plasticity.
Results of the double-blind, placebo-controlled ran-
domized clinical trial of Cbl (30 mL/day for 10 days) in
acute ischemic stroke in Asia has shown favorable outcomes
in patients with National Institutes of Health Stroke Scale
scores >12 who were treated with Cbl [30]. Two large
clinical trials of Cbl as treatment for Alzheimer’s disease
have also been conducted [9,11]. One of the trials studied
the effect of two doses of Cbl (10 mL and 30 mL, 5 days/
week for 4 weeks) on patients with mild to moderately
severe vascular dementia and found that patients who
received Cbl showed better cognitive performance than
patients who received placebo [11]. The other trial studied
the effect of three doses of Cbl (10 mL, 30 mL, and 60 mL
for 12 weeks) on patients with moderate to moderately
severe Alzheimer’s disease and found that patients in all
three Cbl treatment groups had significantly better global
clinical function than patients who received placebo [9].
Zhang et al. [17] reported that Cbl activated Akt in
neural progenitor cells and that blockage of the PI3K/Akt
pathway with a PI3K/Akt inhibitor (LY294002) abolished
Cbl-induced cell proliferation. In our previous study, we
found that granulocyte colony-stimulating factor also
upregulate the PI3K/Akt signaling to protect RGCs from
apoptosis in an animal model of optic nerve crush [2]. Other
studies have shown that Cbl protects against nerve damage
by downregulating microglial activation as well as by con-
trolling IL-1 beta expression [31,32]. Our results demon-
strate that only Cbl administration by systemic applicationtential after cerebrolysin (Cbl) treatment via intravitreal (IVI)
crush. Both Cbl-IVI- and Cbl-IPI-treated groups had shorter P1
phate buffered saline (PBS)-treated group (170  20 ms; ** all
in the Cbl-IONI treatment compared with the PBS-treated group
C Z crush.
Figure 3. At the 3rd week post-crush, ED1þ cells were prominent in the optic nerve (ON) lesion sites in the phosphate buffered
saline-treated group [30  4 cells/high-power field (HPF)]. ED1þ cells were significantly decreased at the ON lesion in the cere-
brolysin (Cbl) treatment via intraperitoneal injection group (5  2 cells/HPF, **p < 0.001). No ED1þ difference was noted between
the Cbl-intravitreal (33  5 cells/HPF), Cbleintra-ON injection (39  9 cells/HPF) and phosphate buffered saline-treatment groups.
n Z 6 in each group. Bar Z 50 mm. C Z crush.
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at the lesion site of optic nerve from the evidence of ED1
stain, which was not decreased in the IVI group. A possible
explanation for this is that there was only one shot in this
IVI group and/or the concentration of drug (0.43 mg/2 mL)
may not have reached the therapeutic level in this optic
nerve crush model. We need further evaluation for optimal
dosage of Cbl in the IVI treatment because of dose-specific
effects [31]. Further in-depth studies for signal pathway
with inhibitors such as PI3K/Akt or ERK pathway with a
PI3K/Akt inhibitor (LY294002) are needed.
In conclusion, systemic administration of Cbl seems to
afford neuroprotection in the rat model of optic nerve
crush, as evidenced by RGCs surviving and visual function
assessment. These findings support the possibility that Cblcan have positive effects in the management of traumatic
optic neuropathy.
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